Omni Bio Pharmaceutical Inc (OMBP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
181 W BOARDWALK DRIVE FORT COLLINS, CO 80525 |
| State of Incorp. | CO |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2014 | 3/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 343,279 | |||
| Cash and cash equivalents | 343,279 | |||
| Other current assets | 41,712 | |||
| Total current assets: | 384,991 | |||
| Noncurrent Assets | ||||
| Intangible assets, net (including goodwill) | 68,407 | |||
| Intangible assets, net (excluding goodwill) | 68,407 | |||
| Regulated entity, other noncurrent assets | 245,653 | |||
| Total noncurrent assets: | 314,060 | |||
| TOTAL ASSETS: | 699,051 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 123,512 | |||
| Accounts payable | 42,512 | |||
| Accrued liabilities | 81,000 | |||
| Total current liabilities: | 123,512 | |||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 226,869 | |||
| Long-term debt, excluding current maturities | 226,869 | |||
| Other undisclosed noncurrent liabilities | 953,326 | |||
| Total noncurrent liabilities: | 1,180,195 | |||
| Total liabilities: | 1,303,707 | |||
| Equity | ||||
| Equity, attributable to parent, including: | (604,656) | |||
| Common stock | 32,018 | |||
| Additional paid in capital | 43,378,278 | |||
| Accumulated deficit | (44,014,952) | |||
| Other undisclosed equity, attributable to parent | ||||
| Total equity: | (604,656) | |||
| TOTAL LIABILITIES AND EQUITY: | 699,051 | |||
Income Statement (P&L) (USD)
| 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|
| Operating expenses | (5,720,243) | ||
| Other undisclosed operating loss | (31,154) | ||
| Operating loss: | (5,720,243) | ||
| Nonoperating expense | (1,734,380) | ||
| Loss from continuing operations before equity method investments, income taxes: | (7,454,623) | ||
| Loss from equity method investments | (780,174) | ||
| Loss from continuing operations: | (8,234,797) | ||
| Loss before gain (loss) on sale of properties: | (8,234,797) | ||
| Other undisclosed net income | 780,174 | ||
| Net loss available to common stockholders, diluted: | (7,454,623) | ||
Comprehensive Income (USD)
| 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|
| Net loss: | (7,454,623) | ||
| Comprehensive loss, net of tax, attributable to parent: | (7,454,623) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.